EBOS traded at 21.91 this Thursday August 6th, decreasing 0.24 or 1.08 percent since the previous trading session. Looking back, over the last four weeks, EBOS lost 0.50 percent. Over the last 12 months, its price fell by 46.82 percent. Looking ahead, we forecast EBOS to be priced at 21.63 by the end of this quarter and at 20.45 in one year, according to Trading Economics global macro models projections and analysts expectations.
Ebos Group Limited is a marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. The Company is also an animal care products marketer and distributor. Its segments include Healthcare, Animal care and Corporate. The Healthcare segment incorporates the sale of healthcare products in a range of sectors, own brands, retail healthcare, wholesale activities and logistics. The Animal care segment incorporates the sale of animal care products in a range of sectors, own brands, retail and wholesale activities. Its businesses include Community Pharmacy, Institutional Healthcare, Contract Logistics and Animal Care. Community Pharmacy includes Symbion, Endeavour Consumer Health, ProPharma, DoseAid and Intellipharm. Institutional Healthcare includes EBOS Healthcare, Onelink, Clinect and Zest. Contract Logistics comprises Healthcare Logistics, Symbion Contract Logistics and Symbion Clinical Trials. Animal Care includes Masterpet, Lyppard, Animates and Vitapet.